Video

Sanjiv Chopra, MD: Future Advances in Artificial Intelligence, Gut Bacteria Research, CRISPR Technology

Author(s):

Dr. Chopra elaborated on his Pri-Med Midwest 2022 presentation regarding the future of advances in medicine, specifically highlighting artificial intelligence, gut microbiome research, and gene editing.

During an interview with HCPLive, Sanjiv Chopra, MD, Professor of Medicine at Harvard Medical School, went into detail on several of his predictions for the 5 key advances set to impact medical science in the future, as part of his Pri-Med Midwest 2022 presentation.

Chopra first went into the topic of the gut microbiome and gastroenterology, a field which he describes as an important one for research in the coming years.

“Success of chemotherapy dictated by the gut microbiota, autism, the study of 18 people given a healthy stool transplant, marked improvement,” he said. “Two years later the microbiome remained changed and (had) marked improvement in GI, psychological, neurological symptoms. So, a fascinating field. It needs to be studied.”

The interview shifted into a discussion of another topic Chopra believes will impact clinicians and researchers in the future: the use of artificial intelligence.

“A recent study from Mayo Clinic published noted 5210 individuals coming to a liver transplant and 27,500 matched controls,” Chopra explained. “Somebody decided to look at the electrocardiogram lead EKG and incorporate artificial intelligence. The EKG predicts cirrhosis and stage liver disease. The most brilliant cardiologist would not be able to see that. Machine learning.”

Chopra later highlighted his views on the future importance of gene editing and CRISPR technology in the modern medical world. He further elaborated on his views regarding the future of psychedelic medicine, the use of ketamine and mushrooms.

Watch the interview above and find out more on these topics from Pri-Med Midwest 2022.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.